BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313-325. [PMID: 20054285 DOI: 10.1097/mcg.0b013e3181c8a1a3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chang SS, Hu HY. Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens. World J Gastrointest Pharmacol Ther 2015; 6(4): 127-136 [PMID: 26558147 DOI: 10.4292/wjgpt.v6.i4.127] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34. [PMID: 22457599 DOI: 10.2147/ceg.s25419] [Cited by in Crossref: 90] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
3 Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases 2016; 4(1): 5-19 [PMID: 26798626 DOI: 10.12998/wjcc.v4.i1.5] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
4 Kanizaj TF, Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014; 20(3): 699-705 [PMID: 24574743 DOI: 10.3748/wjg.v20.i3.699] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
5 Allahverdiyev AM, Bagirova M, Caliskan R, Tokman HB, Aliyeva H, Unal G, Oztel ON, Abamor ES, Toptas H, Yuksel P, Kalayci F, Aslan M, Erzin Y, Bal K, Kocazeybek BS. Isolation and diagnosis of Helicobacter pylori by a new method: Microcapillary culture. World J Gastroenterol 2015; 21(9): 2622-2628 [PMID: 25759529 DOI: 10.3748/wjg.v21.i9.2622] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.e3. [PMID: 25655557 DOI: 10.1053/j.gastro.2015.01.040] [Cited by in Crossref: 233] [Cited by in F6Publishing: 214] [Article Influence: 33.3] [Reference Citation Analysis]
7 Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2013;4:23-27. [PMID: 23667770 DOI: 10.4292/wjgpt.v4.i2.2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol 2015; 21(41): 11654-11672 [PMID: 26556993 DOI: 10.3748/wjg.v21.i41.11654] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
9 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
10 Seyedmajidi MR, Hosseini SA, Vafaeimanesh J. Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in Eradicating Helicobacter Pylori. Middle East J Dig Dis 2021;13:131-8. [PMID: 34712451 DOI: 10.34172/mejdd.2021.216] [Reference Citation Analysis]
11 Fallone CA, Barkun AN, Szilagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013;27:397-402. [PMID: 23862170 DOI: 10.1155/2013/801915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
13 Graham DY, Fischbach LA. Empiric therapies for Helicobacter pylori infections. CMAJ. 2011;183:E506-E508. [PMID: 21343269 DOI: 10.1503/cmaj.101460] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
14 Chen KY, Lin TJ, Lin CL, Lee HC, Wang CK, Wu DC. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. World J Gastroenterol 2015; 21(36): 10435-10442 [PMID: 26420970 DOI: 10.3748/wjg.v21.i36.10435] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
15 Nichol D, Jeavons P, Fletcher AG, Bonomo RA, Maini PK, Paul JL, Gatenby RA, Anderson AR, Scott JG. Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. PLoS Comput Biol 2015;11:e1004493. [PMID: 26360300 DOI: 10.1371/journal.pcbi.1004493] [Cited by in Crossref: 99] [Cited by in F6Publishing: 62] [Article Influence: 14.1] [Reference Citation Analysis]
16 Ben Chaabane N, Al-Adhba HS. Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. Indian J Gastroenterol. 2015;34:68-72. [PMID: 25721770 DOI: 10.1007/s12664-015-0535-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 2015; 21(14): 4345-4357 [PMID: 25892886 DOI: 10.3748/wjg.v21.i14.4345] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 60] [Article Influence: 11.3] [Reference Citation Analysis]
18 Wu JY, Wang SSW, Lee YC, Yamaoka Y, Graham DY, Jan CM, Wang WM, Wu DC. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. World J Gastroenterol 2014; 20(12): 3343-3349 [PMID: 24695835 DOI: 10.3748/wjg.v20.i12.3343] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PMID: 23926315 DOI: 10.1136/bmj.f4587] [Cited by in Crossref: 161] [Cited by in F6Publishing: 156] [Article Influence: 17.9] [Reference Citation Analysis]
20 Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
21 Amin M, Hameed S, Ali A, Anwar F, Shahid SA, Shakir I, Yaqoob A, Hasan S, Khan SA. Green Synthesis of Silver Nanoparticles: Structural Features and In Vivo and In Vitro Therapeutic Effects against Helicobacter pylori Induced Gastritis. Bioinorg Chem Appl. 2014;2014:135824. [PMID: 25214825 DOI: 10.1155/2014/135824] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
22 Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93. [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
23 Saracino IM, Zaccaro C, Re GL, Vaira D, Holton J. The Effects of Two Novel Copper-Based Formulations on Helicobacter pylori. Antibiotics (Basel) 2013;2:265-73. [PMID: 27029303 DOI: 10.3390/antibiotics2020265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol 2014; 20(3): 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
25 John A, Al Kaabi S, Doiphode S, Chandra P, Sharma M, Babu R, Yacoub R, Derbala M. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection? Indian J Gastroenterol 2015;34:404-7. [PMID: 26541342 DOI: 10.1007/s12664-015-0604-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
27 Perrone S, D'Elia GM, Annechini G, Pulsoni A. Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy. Mediterr J Hematol Infect Dis 2016;8:e2016006. [PMID: 26740867 DOI: 10.4084/MJHID.2016.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
28 Lin LC, Hsu TH, Huang KW, Tam KW. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. World J Gastroenterol 2016; 22(23): 5445-5453 [PMID: 27340362 DOI: 10.3748/wjg.v22.i23.5445] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
29 Liu AR, Du YQ. Current status of Helicobacter pylori infection and evolution of treatment strategy in China. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4396-4403 [DOI: 10.11569/wcjd.v24.i32.4396] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;:CD009034. [PMID: 27351542 DOI: 10.1002/14651858.CD009034.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015; 21(1): 351-359 [PMID: 25574111 DOI: 10.3748/wjg.v21.i1.351] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
32 Buzás GM. First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16(31): 3865-3870 [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
33 Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177-186.e3; Discussion e12-e13. [PMID: 23751282 DOI: 10.1016/j.cgh.2013.05.028] [Cited by in Crossref: 195] [Cited by in F6Publishing: 171] [Article Influence: 21.7] [Reference Citation Analysis]
34 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228-013-1524-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
35 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Chan CC, Chien NH, Lee CL, Yang YC, Hung CS, Tu TC, Wu CH. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. [PMID: 26635102 DOI: 10.1186/s12876-015-0401-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
37 Kao SS, Chen WC, Hsu PI, Lai KH, Yu HC, Cheng HH, Peng NJ, Lin CK, Chan HH, Tsai WL. 7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan. Gastroenterol Res Pract. 2012;2012:463985. [PMID: 22888337 DOI: 10.1155/2012/463985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
38 Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. [PMID: 24800203 DOI: 10.1155/2014/124607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
39 Wu W, Yang Y, Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract 2012;2012:723183. [PMID: 22829809 DOI: 10.1155/2012/723183] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
40 Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pyloriWorld J Gastrointest Pharmacol Ther 2013; 4(2): 23-27 [PMID: 23667770 DOI: 10.4292/wjgpt.v4.i2.23] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
41 Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2013;4:23-27. [PMID: 23667770 DOI: 10.4292/wjgpt.v4.i2.23.PubMed] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Asociación Española de Gastroenterología., Sociedad Española de Medicina de Familia y Comunitaria., Centro Cochrane Iberoamericano. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Aten Primaria 2012;44:727.e1-727.e38. [PMID: 23036729 DOI: 10.1016/j.aprim.2012.05.003] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018;29:549-54. [PMID: 30260776 DOI: 10.5152/tjg.2018.17707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol 2013;4:e32. [PMID: 23535826 DOI: 10.1038/ctg.2013.3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
45 Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol 2015; 21(45): 12954-12962 [PMID: 26668516 DOI: 10.3748/wjg.v21.i45.12954] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
46 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
47 Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88. [DOI: 10.1038/nrgastro.2010.210] [Cited by in Crossref: 122] [Cited by in F6Publishing: 129] [Article Influence: 11.1] [Reference Citation Analysis]
48 Zhou Y, Xu QH, Zhou ZJ, Dong YB. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradicating Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2014; 22(19): 2809-2812 [DOI: 10.11569/wcjd.v22.i19.2809] [Reference Citation Analysis]
49 Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:541-548. [PMID: 23929066 DOI: 10.4161/gmic.25930] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
50 Modak JK, Liu YC, Machuca MA, Supuran CT, Roujeinikova A. Structural Basis for the Inhibition of Helicobacter pylori α-Carbonic Anhydrase by Sulfonamides. PLoS One 2015;10:e0127149. [PMID: 26010545 DOI: 10.1371/journal.pone.0127149] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
51 Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 11.1] [Reference Citation Analysis]
52 Morse AL, Goodman KJ, Munday R, Chang HJ, Morse JW, Keelan M, Geary J, Sander Vv; CANHelp Working Group. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. Can J Gastroenterol 2013;27:701-6. [PMID: 24340314 DOI: 10.1155/2013/143047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
53 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859. [PMID: 28207505 DOI: 10.1097/MD.0000000000005859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
55 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Gisbert JP. Enfermedades relacionadas con Helicobacter pylori: dispepsia, úlcera y cáncer gástrico. Gastroenterología y Hepatología 2011;34:16-27. [DOI: 10.1016/s0210-5705(11)70003-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970-1975. [PMID: 21989146 DOI: 10.1038/ajg.2011.306] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
58 Gisbert JP. Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol. 2011;8:307-309. [PMID: 21643037 DOI: 10.1038/nrgastro.2011.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
59 Gisbert JP. [Helicobacter pylori-related diseases: dyspepsia, ulcers and gastric cancer]. Gastroenterol Hepatol 2011;34 Suppl 2:15-26. [PMID: 22330153 DOI: 10.1016/S0210-5705(11)70017-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Marcus EA, Sachs G, Scott DR. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 2016;18:33. [PMID: 27177639 DOI: 10.1007/s11894-016-0509-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
61 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
62 Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol 2015; 21(46): 13124-13131 [PMID: 26673999 DOI: 10.3748/wjg.v21.i46.13124] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
63 Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: Era of antibiotic resistance. World J Gastroenterol 2014; 20(19): 5654-5659 [PMID: 24914324 DOI: 10.3748/wjg.v20.i19.5654] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
64 Graham DY, Rimbara E. Understanding and appreciating sequential therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2011;45:309-13. [PMID: 21389810 DOI: 10.1097/MCG.0b013e31820ac05e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
65 Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012;5:103-109. [PMID: 22423259 DOI: 10.1177/1756283x11432492] [Cited by in Crossref: 78] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
66 Pilotto A, Franceschi M, Maggi S, Addante F, Sancarlo D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging. 2010;27:545-558. [PMID: 20583849 DOI: 10.2165/11537380-000000000-00000] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
67 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pyloriWorld J Gastroenterol 2014; 20(27): 8947-8956 [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
68 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]